Christopher Fenimore Will Succeed Robert Landry in the role of CFO at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), the leading biotechnology company, has officially announced that Robert E. Landry, who currently holds the position of Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024. Following Mr. Landry’s retirement, Christopher Fenimore, the current Senior Vice President and Head of Accounting and Controller at Regeneron, will assume the role of CFO.

Upon assuming the CFO role, Mr. Fenimore will report directly to Dr. Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President, and Chief Executive Officer of Regeneron.

Dr. Schleifer expressed his appreciation for Mr. Landry’s significant contributions to the company during a period of remarkable growth and transformation. He praised Mr. Landry’s steadfast leadership as CFO over the past decade and acknowledged his exceptional work ethic. Dr. Schleifer also extended a warm welcome to Christopher Fenimore, who is set to take over as CFO in early 2024. Dr. Schleifer expressed confidence in Mr. Fenimore, highlighting his strong financial expertise, which will ensure continuity and collaboration across the organization.

Christopher Fenimore has been part of the Regeneron team since 2003. He currently oversees global responsibilities, including U.S. Securities and Exchange Commission reporting, accounting and accounting operations, internal control over financial reporting, accounts payable, and payroll. Additionally, he plays a key role in the company’s international expansion strategy and related initiatives. Before joining Regeneron, Mr. Fenimore served as Vice President of Financial Planning within the organization. Prior to his tenure at Regeneron, he held the position of Vice President of Finance at a biotechnology startup and held various roles in healthcare-focused venture capital and investment banking. Mr. Fenimore began his career as an auditor at KPMG and is a Certified Public Accountant in the state of New York. He holds an M.A. in biotechnology from Columbia University, an MBA in professional accounting from Rutgers Business School, and a B.A. in economics from Rutgers University.

Mr. Fenimore expressed his honor in stepping into the role of Chief Financial Officer at Regeneron. He emphasized his commitment to establishing a unified vision for the company’s continued growth and diversification as a global biopharmaceutical leader. Mr. Fenimore acknowledged the privilege of working alongside Bob and Len over the past two decades, during which Regeneron achieved remarkable financial success and underwent significant transformations. He looks forward to advancing the company’s mission of translating scientific advancements into essential medicines for people worldwide.

Founded and guided by physician-scientists for over 35 years, Regeneron’s unique ability to consistently translate scientific discoveries into medical breakthroughs has resulted in numerous FDA-approved treatments and a robust pipeline of product candidates, the majority of which originated from their in-house laboratories.

Have you read?
Leveraging The Potential of ChatGPT and AI.
How To Integrate eSignature Into Your Business Workflow.
The Importance of Continuous Learning for CEOs.
Navigating Success While Working with Narcissistic Team Members: A CEO’s Perspective.
Why we need to close the gap between developing strategy and implementing it.